In response to a request filed last month by a group of plaintiffs asking to consolidate all Byetta lawsuits, Januvia lawsuits, Janumet lawsuits and Victoza lawsuits filed in the federal…
As concerns have mounted in recent months about the risk of pancreatitis and pancreatic cancer from Januvia, sales of Merck’s blockbuster diabetes drug have taken a sudden dive, contributing to…
Following a request filed by plaintiffs earlier this month to establish a federal MDL for all pancreatic cancer lawsuits involving the diabetes drugs Januvia, Janumet, Byetta and Victoza, Merck has…
Israeli health officials are telling doctors in that country to be on the lookout for signs of pancreatic cancer among users of a popular class of diabetes drugs, known as…
The latest issue of the Institute for Safe Medication Practices (ISMP)’s Quarter Watch, which evaluates adverse event reports submitted to the FDA, highlights the number of pancreatic cancer cases and…
Johnson & Johnson has high hopes that its recently approved diabetes drug, Invokana, will break the trend of problems that have surfaced in recent years with many newer diabetes medications,…
A motion has been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all pancreatic cancer lawsuits filed by former users of Januvia, Janumet, Byetta and Victoza,…
A product liability lawsuit has been filed by the daughter of a Missouri woman who died of pancreatic cancer after Januvia use, alleging that the death was caused by side…
The diabetes drugs Byetta, Januvia, and Victoza are now under investigation by European health officials due to possible ties to pancreatic cancer and pancreatitis.
The findings of new research have identified precancerous changes in the pancreas of diabetes patients who used a class of diabetes drugs known as incretin mimetics, which include Byetta, Januvia,…
